GlobeNewswire

B-Temia and Wistron Join Forces to Launch Keeogo(TM) in Asia

Dela

B-Temia and Wistron form B-Temia Asia to bring Keeogo(TM) to the Asian Market

QUEBEC CITY, June  07, 2018  (GLOBE NEWSWIRE) -- B-Temia Inc., a Canadian biorobotics technology company and market leader in human mobility, entered into a joint venture agreement with Wistron Corporation to launch its Keeogo(TM) Dermoskeleton(TM) technology in Asia. Wistron is one of the world's largest Original Design Manufacturer (ODM), with more than $34 billion CAD sales, and now a major shareholder of B-Temia since June 2017. Wistron and B-Temia form B-Temia Asia for the marketing of Keeogo(TM) in several Asian countries such as China, Japan and Hong Kong. Headquartered in Singapore, B-Temia Asia will benefit from a significant investment from Wistron in exchange for marketing rights for Keeogo(TM) products in Asia.

"B-Temia Asia represents the realization of our business plan and our mission to help people regain their independence through mobility. B-Temia is now expanding around the world, which is another demonstration of the real value of our technology and the need to bring modern and revolutionary solutions to the many people living with mobility limitations. In addition, we are excited to expand and strengthen our partnership with Wistron. Over the last year, both organizations have effectively proven their ability to work together for manufacturing transfer to Asia. This joint venture is the next logical step for Wistron, which became a major shareholder of our company in 2017", said Stéphane Bédard, CEO of B-Temia. "This international expansion is a very exciting time for our shareholders said Mr. Bédard.

"Wistron is advancing the development and application of medical technologies to help people with mobility challenges and we are very excited to increase our partnership with B-Temia and to work closely together to develop the human mobility market in Asia. This partnership directly supports our goal of improving people's lives through technology", said Donald Hwang, Chief Technology Officer (CTO) of Wistron Corporation.

About Keeogo(TM) Dermoskeleton(TM)

Keeogo(TM) is a motorized walking assistive device developed by B-Temia. Keeogo(TM), short for "Keep on Going", has been used by people suffering from degenerative diseases such as osteoarthritis of the knee or hip, multiple sclerosis, Parkinson's disease, stroke, incomplete spinal cord injury and other mobility-limiting diseases. Used as a rehabilitation equipment or as a home assistive device to help with daily activities, Keeogo(TM) is approved by Health Canada and is commercially available in Canada for purchase or rental. For more information, please visit: www.keeogo.com.

About B-Temia

Founded in 2010, B-Temia Inc. is an innovative Canadian medical device manufacturer that develops and markets leading edge products for the growing market of human augmentation systems. B-Temia operates through two wholly owned subsidiaries, B-Temia Inc. and B-Temia USA Inc., in the medical, industrial and military fields. B-Temia has a patented technology called Dermoskeleton(TM) that restores, maintains or enhances user mobility. For more information, please visit: www.b-temia.com.

About Wistron

Wistron Corporation is one of the world's largest companies to produce servers and storage devices for cloud computing and data centers, desktop and laptop computers, smart phones, industrial devices and control units, medical devices, Artificial Intelligence and Big Data Analysis. Wistron's full line of engineering teams enables Wistron's customers to outsource all or part of their product development and manufacturing tasks to focus on their core competencies and further develop their intellectual properties. Wistron manufactures medical products for customers in the medical industry at two ISO 13485-certified factories in Taiwan's Hsinchu Science Park and in Chongqing, China. For more information, please visit: www.wistron.com.

Information

Source:
B-Temia Inc.
4780, St-Félix Street, Suite 105
St-Augustin (Québec) G3A 2J9
www.b-temia.com | www.keeogo.com
Phone: (418) 653-1010
E-mail: info@b-temia.com

 
Media:
Pamela Borges
VP Market Access & External Affairs
Phone: (418) 653-1010, ext. 223
E-mail: pamela.borges@b-temia.com





This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: B-Temia Inc. via Globenewswire

Om

GlobeNewswire



Följ GlobeNewswire

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från GlobeNewswire

Oboya signs a cooperation agreement with Gaia regarding biomaterials13.12.2018 11:41Pressmeddelande

Oboya Horticulture Industries AB (publ) ("Oboya") has signed an important and long-term cooperation agreement on environmentally friendly biomaterials with Gaia Biomaterials AB ("Gaia") in Helsingborg, Sweden. The agreement means that Oboya uses Gaias biomaterials for the production and development of environmentally friendly cultivation products for the cultivation industry. Oboya has been actively involved in innovation, environmental and sustainability issues in recent years, and our goal is to encourage environmental and sustainability in the cultivation industry by offering environmentally friendly cultivation products to our customers. Oboya believes that the use of biomaterials will be important for success in the conversion to a fossil-free cultivation industry worldwide. The cooperation agreement means that Oboya uses Gaias biomaterials in its production and that through Gaias expertise we can develop new environmentally friendly cultivation products. Gaias biomaterials are bi

Oboya tecknar ett samarbetsavtal med Gaia avseende biomaterial13.12.2018 11:41Pressmeddelande

Oboya Horticulture Industries AB (publ) ("Oboya") har tecknat ett viktigt och långsiktigt samarbetsavtal avseende miljövänligt biomaterial med Gaia Biomaterials AB ("Gaia") i Helsingborg, Sverige. Avtalet innebär att Oboya använder Gaias biomaterial för tillverkning och utveckling av miljövänliga odlingsprodukter till odlingsindustrin. Oboya har under de senaste åren arbetat aktivt med innovation, miljö- och hållbarhetsfrågor och vårt mål är att främja miljö och hållbarhet inom odlingsindustrin genom att erbjuda miljövänliga odlingsprodukter till våra kunder. Oboya anser att användningen av biomaterial kommer att vara viktigt för framgång i omställningen till en fossilfri odlingsindustri världen över. Samarbetsavtalet innebär att Oboya använder Gaias biomaterial i sin produktion och att vi genom Gaias kompetens kan utveckla nya miljövänliga odlingsprodukter. Gaias biomaterial är biologiskt nedbrytbart, komposterbart samt ger upp till 80 % lägre koldioxidutsläpp vid förbränning jämfört

Stillfront: Simutronics reclaims publishing services10.12.2018 14:11Pressmeddelande

PRESS RELEASE December 10, 2018 Simutronics reclaims the publishing services for SIEGE: Titan Wars globally except China Simutronics Corp, a studio within Stillfront Group AB, has ended a co-publishing agreement regarding the mobile game SIEGE: Titan Wars with New York based publishing partner Tilting Point. According to a new agreement, Tilting Point will continue to provide publishing services and market the game in China but Simutronics will run the publishing services and marketing globally from the Group going forward. Simutronics is a leading developer of online roleplaying and mobile games such as DragonRealms, GemStone IV and Lara Croft Relic Run, the latter with more than 23 million downloads. Tilting Point is a new-generation games partner that provides top development studios with expert resources, services, and operational support to optimize high quality live games for success. "I am very pleased to continue the partnership with Tilting Point for the Chinese market as this

Stillfront: Simutronics återtar förläggartjänster10.12.2018 14:11Pressmeddelande

PRESSMEDDELANDE 2018-12-10 Simutronics återtar förläggartjänster för SIEGE: Titan Wars globalt med undantag för Kina Simutronics, en studio inom Stillfront Group, har avslutat ett medförläggaravtal avseende mobilspelet SIEGE: Titan Wars med den New York-baserade förläggarpartnern Tilting Point. Enligt ett nytt avtal kommer Tilting Point fortsatt att tillhandahålla förläggartjänster och marknadsföring av spelet i Kina men på global nivå kommer Simutronics att ansvara för förläggartjänster och marknadsföring av spelet från gruppen. Simutronics är en ledande utvecklare av rollspel och mobila spel som till exempel DragonRealms, GemStone IV och Lara Croft Relic Run, den sistnämnda med mer än 23 miljoner nedladdningar. Tilting Point är den nya generationens spelbolagspartner som förser ledande utvecklingsstudios med expertis, tjänster och operationell support för att optimera högkvalitativa livespel framgångsrikt. "Jag är mycket nöjd över det fortsatta partnerskapet med Tilting Point för den

Karolinska Development's portfolio company Aprea Therapeutics presents continued positive results from a Phase Ib/II study of APR 2462.12.2018 18:00Pressmeddelande

STOCKHOLM, December 2, 2018. Karolinska Development's portfolio company Aprea Therapeutics today presented positive clinical results for its drug candidate APR 246 at the 2018 American Society of Hematology (ASH) Annual Meeting in San Diego, US. An Overall Response Rate of 95% and a Complete Remission (CR) rate of 70% were achieved in an ongoing Phase I/II combination study of APR 246 and azacitidine (AZA) for the treatment of TP53 mutated Myelodysplastic Syndrome (MDS). No dose-limiting toxicities have been observed. Based on these encouraging data, Aprea intends to progress APR 246 into a Phase III study in the near future. The results presented at the ASH meeting is based on 20 patients with TP53 mutated MDS. The overall response rate was 95%, and 14 (70%) patients achieved a complete remission at data cutoff. These findings were accompanied by a deep molecular remission in the majority of patients as assessed by serial TP53 analysis. No dose-limiting toxicities have been experience

Karolinska Development's portfolio company Aprea Therapeutics presents continued positive results from a Phase Ib/II study of APR 2462.12.2018 18:00Pressmeddelande

STOCKHOLM, December 2, 2018. Karolinska Development's portfolio company Aprea Therapeutics today presented positive clinical results for its drug candidate APR 246 at the 2018 American Society of Hematology (ASH) Annual Meeting in San Diego, US. An Overall Response Rate of 95% and a Complete Remission (CR) rate of 70% were achieved in an ongoing Phase I/II combination study of APR 246 and azacitidine (AZA) for the treatment of TP53 mutated Myelodysplastic Syndrome (MDS). No dose-limiting toxicities have been observed. Based on these encouraging data, Aprea intends to progress APR 246 into a Phase III study in the near future. The results presented at the ASH meeting is based on 20 patients with TP53 mutated MDS. The overall response rate was 95%, and 14 (70%) patients achieved a complete remission at data cutoff. These findings were accompanied by a deep molecular remission in the majority of patients as assessed by serial TP53 analysis. No dose-limiting toxicities have been experience

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum